default author photo

Aparna Anderson

Gates Medical Research Institute

SCHOLARLY PAPERS

1

DOWNLOADS

201

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Dose-Escalation, Double-Blind, Placebo-Controlled Evaluation of MAM01 Human Monoclonal Antibody for Protection Against Malaria: A First-in-Human, Phase 1 Adaptive Trial

Number of pages: 25 Posted: 23 Jun 2025
Kirsten E. Lyke, Andrea A. Berry, Matthew B. Laurens, Jennifer Winkler, Sudhaunshu Joshi, Abra Rachida Koudjra, Lauryn Butler, Peter F. Billingsley, Tales Pascini, Asha Patil, Kim Lee B. Sim, Grace Fitzgerald, Julie Riegel, Kayla Andrews, Micha Levi, Aparna Anderson, Charles Wells, Hong Liu, James Huleatt and R. Scott Miller
- Center for Vaccine Development and Global Health, - Center for Vaccine Development and Global Health, University of Maryland, Baltimore (UMB) - School of Medicine, affiliation not provided to SSRN, University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute and Gates Medical Research Institute
Downloads 201 (380,469)

Abstract:

Loading...

Malaria, Monoclonal antibody, Plasmodium falciparum, Circumsporozoite Protein, Repeat region, MAM01, Phase 1 trial, Subcutaneous, Intravenous